A sample of SP Laboratories Oxanabol, labeled as containing 10 mg of Oxandrolone per tablet, was independently tested to verify its composition. The analysis, conducted by Janoshik Analytical, revealed that the sample did not contain Oxandrolone as expected. Instead, it was found to contain Methandienone (Dianabol) at 10.08 mg per tablet.
This mislabeling raises significant concerns regarding product authenticity, user safety, and the potential for unintended physiological effects. The sample was procured anonymously by an individual and independently paid for, reducing the risk of manufacturer bias.
Detailed Report
Product Overview
- Manufacturer: SP Laboratories
- Product Name: Oxanabol
- Batch Number: Unknown
- Expiration Date: Unknown
- Delivery Method: Oral tablets
Sample Acquisition and Testing
- Task Number: 51822
- Testing Ordered: 23 OCT 2024
- Sample Received: 31 OCT 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: pinklobster (Individual)
- Analysis Paid For By: pinklobster (Individual)
Verification Details
Verification link:
https://janoshik.com/tests/51822_YZDVEWUGFCZ1
Originally posted: https://thinksteroids.com/community/posts/3444998/
Evaluation of Independent Testing
The findings of this lab report indicate a complete substitution of the declared active ingredient, which presents serious implications for users expecting Oxandrolone but unknowingly ingesting Methandienone. This discrepancy is particularly concerning given the different pharmacological profiles of these substances:
- Oxandrolone is commonly used for muscle retention, recovery, and fat loss with relatively mild androgenic effects.
- Methandienone (Dianabol) is a powerful mass-building anabolic steroid with a much higher propensity for water retention and androgenic side effects.
Such misrepresentation exposes users to potential unexpected side effects, liver toxicity, and altered hormonal responses, reinforcing the importance of independent testing before use.
Conclusion
The tested sample of SP Laboratories Oxanabol failed independent verification, as it did not contain Oxandrolone but rather Methandienone. This substitution is a serious issue, highlighting the risks of relying on unverified sources for performance-enhancing drugs.
Consumers are strongly advised to seek third-party verification before use, as manufacturer claims do not always align with actual product composition. This report underscores the critical role of independent testing in ensuring transparency and harm reduction in the anabolic steroid market.
Disclaimer
This report is published for educational and harm reduction purposes. Independent testing provides valuable insights; however, these findings pertain solely to the analyzed batch and may not represent the entire product line. Consumers are encouraged to critically assess this information alongside additional independent analyses to make informed decisions.
